Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Jul 2022 Status changed from recruiting to completed.
- 01 Dec 2020 Planned End Date changed from 31 Aug 2020 to 31 Mar 2022.
- 03 Jul 2018 Status changed from not yet recruiting to recruiting.